DR2 antigens are associated with severity of disease in toxic oil syndrome (TOS)

Tissue Antigens

Volumn 55, Issue 2, 2000, Pages 110-117

  Cardaba B ^a   Ezendam, J ^a   Gallardo, S ^a   Del Pozo, V ^a   Izquierdo, M ^b   Martin C ^b   Cortegano, I ^a   Aceituno, E ^a   Rojo, M ^a   Arrieta, I ^a   Palomino, P ^a   Posada, M ^b   Lahoz, C ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Disease; DNA typing; DR2; HLA class II antigens; Paraffin embedded tissues; Toxic oil syndrome (TOS)

Indexed keywords

ANILINE; HLA DQ ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; RAPESEED OIL;

ARTICLE; CONTROLLED STUDY; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SPAIN; TOXIC OIL SYNDROME;

ANILINE COMPOUNDS; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE OUTBREAKS; HLA-DR2 ANTIGEN; PARAFFIN EMBEDDING; PLANT OILS; SPAIN; SURVIVORS; SYNDROME;

SINAPIS ARVENSIS; TOSCANA VIRUS;

EID: 0033953430     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2000.550202.x     Document Type: Article

References (36)

1. 1. WHO. Toxic oil syndrome and cosinophiliamyalgia syndrome. Clinical aspects. Report on a workshop. Stony Brook, New York. Copenhagen: WHO Regional Office for Europe, 1992.
2. 2. Abaitua Borda I, Philen RM, Posada de la Paz M et al. Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol 1998: 27: 1057-63.
3. 3. Yoshida SH, German JB, Fletcher MP, Gershwin ME. The Toxic Oil Syndrome: a perspective of immunotoxicological mechanisms. Regulatory Toxicol Pharmacol 1994: 19: 60-79.
4. 4. Heiskanen KM, Savolainen KM. Effects of 3-phenilamino-1, 2-propanediol and its mono-and diolesters on the production of reactive oxygen metabolites in human polymorphonuclear leucocytes. Toxicol Lett 1997: 91: 39-45.
5. 5. Kilbourne EM, Posada de la Paz M, Abaitua Borda I, Diez Ruiz-Navarro M, Philen RM, Falk H. Toxic Oil Syndrome: A current clinical and epidemiologic summary, including comparisons with the Eosinophilia-Myalgia Syndrome. J Am Coll Cardiol 1991: 18:711-7.
6. 6. Kammüller ME, Pennincks AH, Seinen W. Spanish Toxic Oil Syndrome is a chemically induced graft-versus-host-like epidemic. Lancet 1984: 2: 805-6.
7. 7. Kammüller ME, Bloksma N, Seinen W. Autoimmunity and toxicology, immune disregulation induced by drugs and chemicals. In: Kammüller ME, Bloksma N, Seinen W, eds. Autoimmunity and Toxicology. Immune Disregulation Induced by Drugs and Chemicals. Amsterdam: Elsevier, 1989: 4-34.
8. 8. Lahoz C, Tricas I, Vela C, Lauzurica P, Gurbindo C, Garcia R. Hyper IgE, eosinophilia and immunological hyperreactivity due to ingestion of adulterated rapeseed oil (Toxic Oil Syndrome). Eur J Respir Dis 1983: 64: 415-8.
9. 9. Gallardo S, del Pozo V, Cárdaba B et al. Immunological basis of toxic oil syndrome (TOS). Toxicology 1994: 93: 289.
10. 10. Del Pozo V, de Andrés B, Gallardo S et al. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism. Toxicology 1997: 118: 61-70.
11. 11. Ten RM, Kephart GM, Posada M et al. Participation of eosinophils in the toxic oil syndrome. Clin Exp Immunol 1990: 82: 313-7.
12. 12. Kilbourne EM, Bernert JT, Posada de la Paz M et al. Chemical correlates of pathogenicity of oils related to the Toxic Oil Syndrome epidemic in Spain. Am J Epidemiol 1988: 127: 1210-27.
13. 13. Hill RH, Schurz HH, Posada de la Paz M et al. Possible etiologic agents for Toxic Oil Syndrome: fatty acid esters of 3-(N-phenylamino)-1,2-propenediol. Arch Environ Contam Toxicol 1995: 28: 259-64.
14. 14. Posada de la Paz M, Philen RM, Abaitua Borda I et al. Factors associated with pathogenicity of oils related to the Toxic Oil Syndrome Epidemic in Spain. Epidemiology 1994: 5: 404-9.
15. 15. Vicario JL, Serrano-Ríos M, San Andrés F, Arnaiz-Villena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease. Lancet 1982: 1: 276.
16. 16. Miller SA, Dykes D, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1216.
17. 17. Kimura A, Dong RP, Harada H, Sasazuki T. DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 1992: 40: 5.
18. 18. Kimura A, Sasazuki T. Worshop reference protocol of the HLA DNA typing technique. In: Tsuji K, ed. HLA 1991. Vol. 1. Oxford: Oxford University Press, 1992.
19. 19. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994: 43: 18-27.
20. 20. Svejgaard A, Platz P, Ryder LP. HLA and disease 1982: a survey, Immunol Rev 1983: 70: 192-6.
21. 21. Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991: 9: 493-525.
22. 22. Fugger L, Svejgaard A. The HLA-DQ7 and -DQ8 associations in DR4-positive rheumatoid arthritis patients. A combined analysis of data available in the literature. Tissue Antigens 1997: 50: 494-500.
23. 23. Fogdell A, Olerup O, Fredikson S, Vretnem M, Hillert J. Linkage analysis of HLA class II genes in Swedish multiplex families with multiple sclerosis. Neurology 1997: 48: 758-62.
24. 24. Marsh DG, Hsu SH, Roebber M et al. HLA-Dw2: a genetic marker for human immune response to short ragweed pollen allergen Ra5. 1. Response resulting primarily from natural antigenic exposure. J Exp Med 1982: 155: 1439-47.
25. 25. Cárdaba R, Vilches C, Martin E et al. DR7 and DQ2 are positively associated with immunoglobulin. E response to the main antigen of olive pollen (Ole e I) in allergic patients. Hum Immunol 1993: 38: 293-9.
26. 26. Tabuenca JM. Toxic-allergic shock syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981: 2: 567-8.
27. 27. Alonso-Ruíz A, Calabozo M, Pérez RF, Mancebo L. Toxic oil syndrome. A long term cohort of 322 patients. Medicine Baltimore 1993: 72: 285-95.
28. 28. Arnáiz-Villena A, Vicario JL, Serrano-Ríos M, Bellas MD, Mampaso MD. Glomerular basement-membrane antibodies and HLA-DR2 in Spanish rapeseed oil disease (letter). N Engl J Med 1982: 307: 1404-5.
29. 29. Arnáiz-Villena A, Vicario JL, San Andrés F, Serrano Ríos M. Factures genéticos de predisposición al estadío crónico del Síndrome Tóxico: HLA y sexo. Proc Symposium National del Sídrome Tóxico 1982: 1: 174-7.
30. 30. Arnáiz-Villena A, Martínez-Laso J, Corell A et al. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome. Eur J Immunogenet 1996: 23: 211-.
31. 31. Berking C, Hobbs MV, Chatelain R, Meurer M, Bell SA. Strain-dependent cytokine profile and susceptibility to oleic acid anilide in a murine model of the Toxic Oil Syndrome. Toxicol Applied Pharmacol 1998: 148: 222-8.
32. 32. Kubieka-Muranyi M, Goebels R, Goebel C, Uetrecht J, Gleichmann E. T lymphocytes ignore procainamine, but respond to its reactive metabolits in peritoneal cells: Demonstration by the adoptive transfer popliteal lymph node assay. Toxicol Appl Pharmacol 1993: 122: 88-94.
33. 33. De Andrés B, del Pozo V, Gallardo S et al. Improved method for mRNA extraction from paraffin-embedded tissues. Biotechniques 1995: 18: 42-3.
34. 34. Heller MJ, Robinson RA, Burgart LJ, TenEyck CJ, Wilke WW. DNA extraction by sonication: A comparison of fresh, frozen, and paraffin-embedded tissues extracted for use in polymerase chain reaction assays. Methods Pathol 1992: 6: 203-6.
35. 35. Bateman AC, Sage DA, Al-Talib RK, Theaker JM, Jones DB, Howell WM. Investigation of specimen mislabelling in paraffin-embedded tissue using a rapid, allele-specific, PCR-based HLA class II typing method. Histopathology 1996: 28: 169-74.
36. 36. Bierhuizen MF, Maemura K, Kudo S, Fukuda M. Human beta-1, 6-N-acetylglucosaminyltransferase (IGnT) gene, and translated products. Glycobiology 1995: 5: 417-25.